These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29668893)

  • 41. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
    Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
    Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
    [No Abstract]   [Full Text] [Related]  

  • 43. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
    Papamichael K; Stocco G; Ruiz Del Agua A
    Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
    Little RD; Swaine A; Reynolds R; Gibson DJ; Barrau M; D'Errico F; Hampal R; Sparrow MP; Roblin X; Irving PM; Ward MG
    Inflamm Bowel Dis; 2023 Nov; ():. PubMed ID: 37951220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients.
    Bultman E; de Haar C; van Liere-Baron A; Verhoog H; West RL; Kuipers EJ; Zelinkova Z; van der Woude CJ
    Aliment Pharmacol Ther; 2012 Feb; 35(3):335-41. PubMed ID: 22191671
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
    Anjie SI; Hanzel J; Gecse KB; D'Haens GR; Brandse JF
    Scand J Gastroenterol; 2024; 59(2):169-175. PubMed ID: 37961895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings.
    Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S
    Intern Med J; 2021 May; 51(5):739-745. PubMed ID: 31589357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
    Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
    Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study.
    Pouillon L; Lamoureux A; Pineton de Chambrun G; Vuitton L; Pariente B; Zallot C; Dufour G; Fumery M; Baumann C; Amiot A; Nancey S; Rousseau H; Peyrin-Biroulet L
    Dig Liver Dis; 2019 Feb; 51(2):236-241. PubMed ID: 30502230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
    Guidi L; Pugliese D; Panici Tonucci T; Berrino A; Tolusso B; Basile M; Cantoro L; Balestrieri P; Civitelli F; Bertani L; Marzo M; Felice C; Gremese E; Costa F; Viola F; Cicala M; Kohn A; Gasbarrini A; Rapaccini GL; Ruggeri M; Armuzzi A
    J Crohns Colitis; 2018 Aug; 12(9):1079-1088. PubMed ID: 29860436
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease.
    Ancona S; Signa S; Longo C; Cangemi G; Carfora R; Drago E; La Rosa A; Crocco M; Chiaro A; Gandullia P; Arrigo S
    World J Gastroenterol; 2023 Oct; 29(38):5428-5434. PubMed ID: 37900586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
    Russo EA; Iacucci M; Lindsay JO; Campbell S; Hart A; Hamlin J; Orchard T; Arebi N; Nightingale J; Jacyna MR; Gabe SM; O'Connor M; Harris AW; O'Morain C; Ghosh S
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):334-9. PubMed ID: 19528808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
    Wu JF
    Gut Liver; 2022 Jul; 16(4):515-524. PubMed ID: 34670875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
    Martelli L; Olivera P; Roblin X; Attar A; Peyrin-Biroulet L
    J Gastroenterol; 2017 Jan; 52(1):19-25. PubMed ID: 27665099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimizing biological therapy in Crohn's disease.
    Gecse KB; Végh Z; Lakatos PL
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):37-45. PubMed ID: 26471077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
    Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
    Papamichael K; Cheifetz AS
    Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.